

Global Antiretroviral Drugs Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023

<https://marketpublishers.com/r/G4B4DDE645DEN.html>

Date: November 2017

Pages: 224

Price: US\$ 4,400.00 (Single User License)

ID: G4B4DDE645DEN

Abstracts

Antiretroviral Drugs Market

Retroviruses is a single stranded RNA containing virus with DNA intermediate. Retrovirus use enzyme, reverse transcriptase to copy their RNA into DNA of the host cell. The retrovirus integrates its viral DNA into DNA of the host cell, which allows the retrovirus to replicate. Retroviruses can cause different outcomes for the infected cell. Retroviruses are capable of inducing autoimmune, immunosuppressive, and neurological illnesses. Some retroviruses, such as the spumaviruses and lentiviruses are capable of directly killing cells.

Cytopathic effects in cells in the brain and infected T cells may develop immune deficiencies and neurological diseases induced by HIV and related lentiviruses. Retrovirus causes immunological diseases including HIV and T-Cell leukaemia. Acquired immune deficiency syndrome (AIDS) caused by retrovirus known as human immunodeficiency virus (HIV) and T-Cell leukaemia caused by human T lymphotropic virus (HTLV). Antiretroviral drugs are the drugs that acts or inhibit certain process in viral replication and inhibits further worsening of the diseases.

Globally antiretroviral drugs market driven by increased cases of retroviral infections such as especially HIV/AIDS. According to WHO, 36.7 million people were diagnosed with HIV/AIDS in 2015, whereas, 1.1 million people died of AIDS related illness in the same year. The higher prevalence of HIV owing to the various factors such as lack of availability of medication for the treatment of HIV infection, promising pipeline drugs, increased funding by the government are expected to bolster the antiretroviral drugs market over the forecast period. However, high costs of R&D and stringent regulatory

procedures hampering the antiretroviral drugs market. Furthermore, availability of the generic versions of blockbuster drugs affecting the market revenue of antiretroviral drugs.

Global antiretroviral drugs market is segmented based on drug class, route of administration, and distribution channel

Based on drug class, antiretroviral drugs are classified into

Nucleoside Reverse Transcriptase Inhibitors (NRT's)

Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT's)

Protease Inhibitors

Integrate Inhibitors

Fusion Inhibitors

Chemokine Receptor Inhibitors

Others

Based on route of administration, antiretroviral drugs are classified into

Oral

Parenteral

Based on distribution channel, antiretroviral drugs market is classified into

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Others

Antiretroviral drugs market is expected to grow at significant rates during forecasting period owing to pipeline drugs such as doravirine (Merck & Co.), fostemsavir (Bristol-Myers Squibb), rilpivirine (Tibotec) etc. Market players are adopting strategies like mergers and acquisitions to improve the market share. In December 2015, ViiV Healthcare purchased Bristol-Myers Squibb's late stage HIV R&D assets. Market players are also actively collaborating with government and non-government organizations to educate the people and increase awareness related to retroviral diseases. For instance, in September 2016, in an effort to eradicate and combat HIV/AIDS and hypertension in Africa, under U.S. Presidents Emergency Plan for Aids Relief (PEPFAR), United States partnered with AstraZeneca Plc in donating US\$10 million to HIV/AIDS funding.

Geographically antiretroviral drugs market is segmented into five key regions Viz. North America, Europe, Asia- Pacific, Latin America, and Middle East & Africa. North America antiretroviral market is driven by introduction of combination therapies such as antiretroviral therapy dosages by key players in the region. Asia Pacific region expected to be fastest growing due to developing healthcare infrastructure and increase in government and non-government organization initiatives creating awareness of retroviral diseases especially HIV/AIDS. Asia Pacific region has many generic drug manufacturing companies that are already have significant presence in global retroviral drugs in market. Middle East and Africa region is expected to be key region owing to availability of large pool of patients with retroviral diseases. However, poor healthcare infrastructure and lack of awareness related to retroviral diseases among healthcare professionals expected to hamper market revenue growth in the region.

Some of the players in the antiretroviral drugs market are Abbott Laboratories (U.S.), AstraZeneca plc (U.K.), Modified Polymer Components, Inc. (Bristol-Myers-Squibb) (U.S), Gilead Sciences (U.S.), GlaxoSmithKline Plc (U.K.), and F. Hoffmann-La Roche AG (Switzerland) to name a few

In November 2016, ViiV Healthcare (Pfizer and GlaxoSmithKline's joint venture) received U.S. FDA approval to market selzentry for the treatment of CCR5-tropic HIV-1 infection, in combination with other antiretroviral agents.

Report Outline:

The report provides granular level information about the market size, regional market share and forecast from 2017-2023

The report covers in-detail insights about the competitor's overview, key findings and their key strategies

The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry

The report tracks recent innovations, key developments and startup's details that are working in the industry

The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL ANTIRETROVIRAL DRUGS MARKET INTRODUCTION

2.1. Global Antiretroviral Drugs Market – Taxonomy

2.2. Global Antiretroviral Drugs Market –Definitions

2.2.1. Drug Class

2.2.2. Route of Administration

2.2.3. Distribution Channel

3. GLOBAL ANTIRETROVIRAL DRUGS MARKET DYNAMICS

3.1. Drivers

3.2. Restraints

3.3. Opportunities/Unmet Needs of the Market

3.4. Trends

3.5. Global Antiretroviral Drugs Market Dynamics – Factors Impact Analysis

3.6. Global Antiretroviral Drugs Market – Regulations

3.6.1. U.S

3.6.2. Europe

3.6.3. Japan

3.6.4. China

3.7. Global Antiretroviral Drugs Market – Product Innovations

4. GLOBAL ANTIRETROVIRAL DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

4.3. Market Opportunity Analysis

5. GLOBAL ANTIRETROVIRAL DRUGS MARKET, BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Nucleoside Reverse Transcriptase Inhibitors (NRT's)

5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

- 5.1.3. Market Opportunity Analysis
- 5.2. Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT's)
 - 5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
 - 5.2.3. Market Opportunity Analysis
- 5.3. Protease Inhibitors
 - 5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
 - 5.3.3. Market Opportunity Analysis
- 5.4. Integrase Inhibitors
 - 5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
 - 5.4.3. Market Opportunity Analysis
- 5.5. Fusion Inhibitors
 - 5.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
 - 5.5.3. Market Opportunity Analysis
- 5.6. Chemokine Receptor Inhibitors
 - 5.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
 - 5.6.3. Market Opportunity Analysis
- 5.7. Others
 - 5.7.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
 - 5.7.3. Market Opportunity Analysis

6. GLOBAL ANTIRETROVIRAL DRUGS MARKET FORECAST, BY ROUTE OF ADMINISTRATION, 2012 - 2016 AND FORECAST, 2017 - 2023

- 6.1. Parenteral
 - 6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
 - 6.1.3. Market Opportunity Analysis
- 6.2. Oral
 - 6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
 - 6.2.3. Market Opportunity Analysis

7. GLOBAL ANTIRETROVIRAL DRUGS MARKET FORECAST, BY DISTRIBUTION

CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Retail Pharmacies

7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

7.1.3. Market Opportunity Analysis

7.2. Hospital Pharmacies

7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

7.2.3. Market Opportunity Analysis

7.3. Online Pharmacies

7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

7.3.3. Market Opportunity Analysis

7.4. Others

7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

7.4.3. Market Opportunity Analysis

8. GLOBAL ANTIRETROVIRAL DRUGS MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. North America

8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

8.1.3. Market Opportunity Analysis

8.2. Europe

8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

8.2.3. Market Opportunity Analysis

8.3. Asia-Pacific

8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

8.3.3. Market Opportunity Analysis

8.4. Latin America

8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

8.4.3. Market Opportunity Analysis

8.5. Middle East and Africa

- 8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 8.5.3. Market Opportunity Analysis

8.6. Global Antiretroviral Drugs Market - Opportunity Analysis Index, By Drug Class, Route of administration, Distribution Channel and Region, 2017 – 2023

9. NORTH AMERICA ANTIRETROVIRAL DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

9.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

- 9.1.1. Nucleoside Reverse Transcriptase Inhibitors (NRT's)
- 9.1.2. Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT's)
- 9.1.3. Protease Inhibitors
- 9.1.4. Integrase Inhibitors
- 9.1.5. Fusion Inhibitors
- 9.1.6. Chemokine Receptor Inhibitors
- 9.1.7. Others

9.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

- 9.2.1. Parenteral
- 9.2.2. Oral

9.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

- 9.3.1. Retail Pharmacies
- 9.3.2. Hospital Pharmacies
- 9.3.3. Online Pharmacies
- 9.3.4. Others

9.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

- 9.4.1. U.S.
- 9.4.2. Canada

9.5. North America Antiretroviral Drugs Market - Opportunity Analysis Index, By Drug Analysis, Route of Administration, Distribution Channel, and Country, 2017 – 2023

9.6. North America Antiretroviral Drugs Market Dynamics – Trends

10. EUROPE ANTIRETROVIRAL DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

10.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

- 10.1.1. Nucleoside Reverse Transcriptase Inhibitors (NRT's)
- 10.1.2. Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT's)
- 10.1.3. Protease Inhibitors
- 10.1.4. Integrate Inhibitors
- 10.1.5. Fusion Inhibitors
- 10.1.6. Chemokine Receptor Inhibitors
- 10.1.7. Others

10.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

- 10.2.1. Parenteral
- 10.2.2. Oral

10.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

- 10.3.1. Retail Pharmacies
- 10.3.2. Hospital Pharmacies
- 10.3.3. Online Pharmacies
- 10.3.4. Others

10.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

- 10.4.1. Germany
- 10.4.2. UK
- 10.4.3. France
- 10.4.4. Spain
- 10.4.5. Italy
- 10.4.6. Russia
- 10.4.7. Poland
- 10.4.8. Rest of Europe

10.5. Europe Antiretroviral Drugs Market - Opportunity Analysis Index, By Drug Analysis, Route of Administration, Distribution Channel, and Country, 2017 – 2023

10.6. Europe Antiretroviral Drugs Market Dynamics – Trends

11. ASIA-PACIFIC ANTIRETROVIRAL DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

11.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

- 11.1.1. Nucleoside Reverse Transcriptase Inhibitors (NRT's)

- 11.1.2. Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT's)
- 11.1.3. Protease Inhibitors
- 11.1.4. Integrate Inhibitors
- 11.1.5. Fusion Inhibitors
- 11.1.6. Chemokine Receptor Inhibitors
- 11.1.7. Others
- 11.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
 - 11.2.1. Parenteral
 - 11.2.2. Oral
- 11.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
 - 11.3.1. Retail Pharmacies
 - 11.3.2. Hospital Pharmacies
 - 11.3.3. Online Pharmacies
 - 11.3.4. Others
- 11.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
 - 11.4.1. Japan
 - 11.4.2. China
 - 11.4.3. India
 - 11.4.4. ASEAN
 - 11.4.5. Australia & New Zealand
 - 11.4.6. Rest of Asia-Pacific
- 11.5. Asia-Pacific Antiretroviral Drugs Market - Opportunity Analysis Index, By Drug Analysis, Route of Administration, Distribution Channel, and Country, 2017 – 2023
- 11.6. Europe Antiretroviral Drugs Market Dynamics – Trends

12. LATIN AMERICA ANTIRETROVIRAL DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

- 12.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
 - 12.1.1. Nucleoside Reverse Transcriptase Inhibitors (NRT's)
 - 12.1.2. Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT's)
 - 12.1.3. Protease Inhibitors
 - 12.1.4. Integrate Inhibitors
 - 12.1.5. Fusion Inhibitors

12.1.6. Chemokine Receptor Inhibitors

12.1.7. Others

12.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.2.1. Parenteral

12.2.2. Oral

12.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.3.1. Retail Pharmacies

12.3.2. Hospital Pharmacies

12.3.3. Online Pharmacies

12.3.4. Others

12.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.4.1. Brazil

12.4.2. Mexico

12.4.3. Argentina

12.4.4. Venezuela

12.4.5. Rest of Latin America

12.5. Latin America Antiretroviral Drugs Market - Opportunity Analysis Index, By Drug Analysis, Route of Administration, Distribution Channel, and Country, 2017 – 2023

12.6. Latin America Antiretroviral Drugs Market Dynamics – Trends

13. MIDDLE EAST AND AFRICA ANTIRETROVIRAL DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

13.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.1.1. Nucleoside Reverse Transcriptase Inhibitors (NRT's)

13.1.2. Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT's)

13.1.3. Protease Inhibitors

13.1.4. Integrate Inhibitors

13.1.5. Fusion Inhibitors

13.1.6. Chemokine Receptor Inhibitors

13.1.7. Others

13.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.2.1. Parenteral

13.2.2. Oral

13.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.3.1. Retail Pharmacies

13.3.2. Hospital Pharmacies

13.3.3. Online Pharmacies

13.3.4. Others

13.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.4.1. Brazil

13.4.2. Mexico

13.4.3. Argentina

13.4.4. Venezuela

13.4.5. Rest of Latin America

13.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.5.1. Gulf Cooperation Council (GCC) Countries

13.5.2. Israel

13.5.3. South Africa

13.5.4. Rest of MEA

13.6. MEA Antiretroviral Drugs Market - Opportunity Analysis Index, By Drug Analysis, Route of Administration, Distribution Channel, and Country, 2017 – 2023

13.7. MEA Antiretroviral Drugs Market Dynamics – Trends

14. COMPETITION LANDSCAPE

14.1. Strategic Dashboard of Top Market Players

14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)

14.2.1. Abbott Laboratories (U.S.)

14.2.2. AstraZeneca plc (U.K.)

14.2.3. Modified Polymer Components, Inc. (Bristol-Myers-Squibb) (U.S)

14.2.4. Gilead Sciences (U.S.)

14.2.5. GlaxoSmithKline Plc (U.K.)

14.2.6. F. Hoffmann-La Roche AG (Switzerland)

15. RESEARCH METHODOLOGY

16. KEY ASSUMPTIONS AND ACRONYMS

I would like to order

Product name: Global Antiretroviral Drugs Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023

Product link: <https://marketpublishers.com/r/G4B4DDE645DEN.html>

Price: US\$ 4,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G4B4DDE645DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

